scispace - formally typeset
E

Eugenio Fernandez

Researcher at Geneva College

Publications -  13
Citations -  1343

Eugenio Fernandez is an academic researcher from Geneva College. The author has contributed to research in topics: Talimogene laherparepvec & Pembrolizumab. The author has an hindex of 7, co-authored 12 publications receiving 989 citations.

Papers
More filters
Journal ArticleDOI

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Antoni Ribas, +19 more
- 07 Sep 2017 - 
TL;DR: The findings suggest that oncolytic virotherapy may improve the efficacy of anti-PD-1 therapy by changing the tumor microenvironment.
Journal ArticleDOI

Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

Georgina V. Long, +19 more
- 20 May 2016 - 
TL;DR: T-VEC significantly improved durable response rate vs GM-CSF in stage IIIB-IV melanoma patients (pts) with injectable tumors and the combination may further improve clinical benefit.
Journal ArticleDOI

Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027))

Antoni Ribas, +19 more
- 09 Aug 2018 - 
Journal ArticleDOI

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)

Georgina V. Long, +17 more
- 04 Nov 2015 - 
TL;DR: T-VEC is a herpes simplex virus-1-based oncolytic immunotherapy designed to selectively replicate in tumors, produce GM-CSF, and stimulate antitumor immune responses.
Journal ArticleDOI

24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma

Georgina V. Long, +17 more
- 01 Sep 2015 -